Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.

This review highlights the potential for physical exercise to reduce treatment toxicity and modification rates in patients with metastatic colorectal cancer receiving systemic treatments, suggesting benefits for survival outcomes; it recommends further trials to confirm these findings.

This review highlights the diverse cutaneous manifestations in immunocompromised patients, emphasizing the importance of early recognition for improved patient prognosis.

This study found that tumor immunotherapy, while effective against solid tumors, can disrupt the immune balance in hair follicles, causing follicular toxicity and alopecia, highlighting the need for targeted interventions to manage these adverse effects.

This study observed that 2.5% of patients with mycosis fungoides or Szary syndrome experienced alopecia, predominantly within skin lesions, with scalp metastases from other cancers also potentially causing hair loss, highlighting the diagnostic value of trichoscopy in differentiating alopecia types.

This review discusses the heterogeneity of Tregs in normal and tumor environments, emphasizing the complexity of targeting tumor-resident Tregs while maintaining systemic immune tolerance, but reports no new findings.

This opinion piece discusses strategies for managing cancer-related alopecia, emphasizing personalized approaches including scalp cooling and topical minoxidil, but it reports no new clinical results.

In this case report, the authors documented a fatal instance of Stevens-Johnson syndrome in an elderly woman potentially triggered by doxycycline and flucloxacillin, emphasizing the importance of recognizing such rare but severe drug reactions in older patients.

This review highlights recent advances in dermatology, including innovations in skin cancer treatments, acne and psoriasis management, trends in cosmetic procedures, and the impact of telemedicine, emphasizing ongoing research's role in enhancing patient care and outcomes.

Continuous glucose monitoring and GLP-1 receptor agonists improve diabetes management, but personalized care and education are crucial.

In this review, chemotherapy-induced alopecia in cancer patients is linked to drug pharmacology, genetics, and nutrition, affecting patients' mental health; scalp cooling is highlighted as an effective prevention method, but more research is needed for broader solutions.

This article discusses the potential benefits of GcMAF and oral MAF, developed by "Saisei Mirai", for cancer and other conditions, but reports no new clinical results.

This study found that patients with chronic kidney disease-associated pruritus had elevated serum levels of interleukin 31, suggesting a possible role of this cytokine in the condition.

This review reports the first known case of hair repigmentation associated with lamivudine use and examines mechanisms related to drug-induced hair repigmentation, suggesting potential therapeutic strategies for reversing hair graying.

This review discusses the adnexotropic presentations of interface dermatitides and highlights the importance of recognizing adnexal involvement to aid in accurate diagnosis and avoid misinterpretation.

This abstract lists a range of drugs and treatment agents like Abatacept, Amiodarone, and Remdesivir, but does not report any study results or findings.

This article provides issue information for the September 2020 edition of the British Journal of Dermatology and contains no new research findings.

This review discusses medications used in dermatology, detailing their side effects and interactions, and reports no new clinical results.

This article provides a reference guide for various dermatological terms, treatments, and conditions, but reports no new clinical findings.

In this study, researchers observed that dormant TRP-2+ melanoma cells in bone marrow can interact with CD8+ T cells in tumor-bearing ret transgenic mice, potentially influencing immune responses.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

This study found that Pmab treatment may alter hair follicle growth cycles, leading to trichomegaly and hypertrichosis, but these effects do not correlate with other skin toxicities.

This case report describes a woman with alopecia universalis, resistant to multiple treatments, who experienced successful hair regrowth with adalimumab, suggesting potential mechanisms for future investigation.

This case report documents the first use of bimekizumab as monotherapy for dissecting cellulitis of the scalp, where a 27-year-old man experienced significant symptom relief without adverse effects after failing standard treatments.

This study reviewed the use of dupilumab, beyond its approved indications for atopic dermatitis and prurigo nodularis, and found effective treatment reports for various chronic inflammatory skin diseases such as bullous autoimmune diseases, eczema, and alopecia areata, highlighting its broad potential in dermatology.

Panitumumab can cause excessive ear hair growth.

This phase Ib study found that combining pegylated liposomal doxorubicin and pembrolizumab was well-tolerated and effective, with durable antitumor responses and a median survival of over two years in heavily pretreated ER-positive metastatic breast cancer patients.

This study reported that dupilumab, an FDA-approved biologic, is a safe and effective first-line systemic treatment for children with moderate-to-severe atopic dermatitis, showing sustained skin improvement and itch reduction, with injection site reactions and conjunctivitis as potential side effects.

This case report describes a 19-year-old patient with microsatellite stable adrenocortical carcinoma who showed a promising 36-month response to pembrolizumab, including structural and biochemical improvements, with primary adrenal insufficiency as a major side effect.

In this study, among 450 patients treated with immune checkpoint inhibitors for metastatic melanoma, 1.33% developed scarring alopecia, all being female, with alopecia not impacting their cancer treatment continuation and a favorable cancer outcome reported.